Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation

Clinical Cancer Research

Volumn 14, Issue 5, 2008, Pages 1455-1463

  Laheru, Dan ^a   Lutz, Eric ^b   Burke, James ^c   Biedrzycki, Barbara ^a   Solt, Sara ^b   Onners, Beth ^a   Tartakovsky, Irena ^a   Nemunaitis, John ^d   Le, Dung ^a   Sugar, Elizabeth ^a,b   Hege, Kristen ^c   Jaffee, Elizabeth ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c CELL GENESYS INC   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HLA ANTIGEN CLASS 1; MESOTHELIN;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CELL THERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DISEASE COURSE; DIZZINESS; DRUG SAFETY; DRY SKIN; EXTREMITY PAIN; FATIGUE; FEMALE; FEVER; HEADACHE; HOT FLUSH; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; INFLAMMATION; INJECTION SITE DISCOLORATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE VESICLE; MALE; METASTASIS; MONOTHERAPY; MYALGIA; NAUSEA; NIGHT SWEAT; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; RASH; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PILOT PROJECTS; SURVIVAL RATE; TISSUE DISTRIBUTION;

EID: 40949157885     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0371     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2006. CA Cancer J Clin 2006;56:106-30.
2. Yeo CJ, Pluth-Yeo T, Hruban R, et al. Cancer of the pancreas. In: DeVita VT, editor. Principles and practice of oncology, 7th edition. Philadelphia: J.B. Lippincott Co.; 2005. p. 945-86.
3. Burris HA, Moore MJ, Cripps MC, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
4. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52.
5. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83.
6. Tempero M, Plunkett W, van Haperen VR, et al. Randomized phase II comparison of dose intense Gemcitabine: thirty minute infusion and fixed dose infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402-8.
7. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16.
8. Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006;27:4441-7.
9. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005;16:1639-45.
10. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-6.
11. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. JClin Oncol 2007;25:1960-6.
12. Ko A, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 2006;24:379-85.
13. DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG. Fluorouracil and high dose leukovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991;9:2128-33.
14. Crown J, Casper ES, Botet J, Murray P, Kelsen DP. Lack of efficacy of high dose leukovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991;9:1682-6.
15. Rothenberg ML, Benedetti JK, Macdonald JS, et al. Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Ann Oncol 2002;13:1576-82.
16. Kindler HL. Pancreatic cancer: an update. Curr Oncol Rep 2007;9:170-6.
17. Burris HA, Rivkin S, Reynolds R, et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 2005;10:183-90.
18. Ulrich-Pur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs. raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003;88:1180-4.
19. Kozuch P, Grossbard ML, Barzdins A, et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leukovorin and cisplatin (G-FLIP) is an effective and non-cross resistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001;6:488-95.
20. Reni M, Panucci MG, Passoni P, et al. Salvage chemotherapy with mitomycin, docetaxel and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest 2004;22:688-96.
21. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
22. Hruban RH, Van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the pancreas. Am J Pathol 1993;143:545-54.
23. Gjertsen MK, Bakka A, Breivik J, et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding ras mutation. Lancet 1995;346:1399-400.
24. Finn OJ, Jerome KR, Henderson RA, et al. MUC-1 epithelial tumor mucin-based immunity and vaccines. Immunol Rev1995;145:61-89.
25. Apostopopoulos V, McKenzie IF. Cellular mucins: targets for immunotherapy. Crit Rev Immunol 1994;14:293-309.
26. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81.
27. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-40.
28. Morse M, Clay T, Hobeika A, et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005;11:3017-24.
29. Ramanathan RK, Lee KM, McKolanis J, et al. A phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54:254-64.
30. Gilliam AD, Watson SA. G17DT: an anti-gastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther 2007;7:397-404.
31. Harris JC, Gilliam AD, McKenzie AJ, et al. The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas. Cancer Res 2004;64:5624-31.
32. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone or sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte-macrophage colony stimulating factor, in patients with carcinoembryonic antigen-expressing carcinoma. J Clin Oncol 2005;23:720-31.
33. Jaffee EM, Hruban R, Biedrzycki B, et al. A novel allogeneic GM-CSF secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-56.
34. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8+ T cell responses provide evidence of in vivo cross priming by antigen presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297-306.
35. Berd D, Maguire H, Mastrangelo M. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986;46:2572-7.
36. Holmberg L, Sandmaier B. Theratope vaccine. Expert Opin Biol Ther 2001;1:881-91.
37. Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high avidity CD8+ Tcells to the antitumor immune response. J Exp Med 2005;201:1591-602.
38. Jaffee EM, Thomas MC, Huang AYC, Hauda KM, Levitsky HI, Pardoll DM. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother 1996;19:52-60.
39. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
40. Thomas MC, Greten T, Jaffee EM. Vaccination with allogeneic tumor cells induces specific anti-tumor immunity. Hum Gene Ther 1998;9:835-43.